World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Paul J. Mellett, Jr. net worth and biography

Paul Mellett, Jr. Biography and Net Worth

Sr. VP of Fin. & Admin. and CFO of Enanta Pharmaceuticals

Mr. Mellett joined Enanta in September 2003. Prior to joining Enanta, he held the position of Senior Vice President and Chief Financial Officer of Essential Therapeutics. Previously, Mr. Mellett was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. Mr. Mellett also served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries, which was acquired by Fluor Corporation. Earlier in his career, Mr. Mellett was employed with Deloitte & Touche LLP, a public accounting firm, where he served as Audit Partner. Mr. Mellett received a B.S. in Business Administration from Boston College.

How do I contact Paul J. Mellett, Jr.?: The corporate mailing address for Mr. Mellett, Jr. and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at [email protected]. Learn More on Paul J. Mellett, Jr.'s contact information.
Has Paul J. Mellett, Jr. been buying or selling shares of Enanta Pharmaceuticals?: Paul J. Mellett, Jr. has not been actively trading shares of Enanta Pharmaceuticals in the last ninety days. Learn More on Paul J. Mellett, Jr.'s trading history.
Who are Enanta Pharmaceuticals' active insiders?: Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Jay Luly (CEO), and Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ). Learn More on Enanta Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Enanta Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 27,596 shares worth more than $257,949.03. The most recent insider tranaction occured on December, 13th when Director Terry Vance sold 15,295 shares worth more than $139,490.40. Insiders at Enanta Pharmaceuticals own 13.6% of the company. Learn More about insider trades at Enanta Pharmaceuticals.
Information on this page was last updated on 12/13/2023.

Paul J. Mellett, Jr. Insider Trading History at Enanta Pharmaceuticals

Paul J. Mellett, Jr. Buying and Selling Activity at Enanta Pharmaceuticals

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $12.48

$12.40

$12.74

50 Day Range

MA: $14.84

$12.48

$17.46

2 Week Range

Now: $12.48

$8.08

$37.75

Volume

79,696 shs

Average Volume

254,185 shs

Market Capitalization

$264.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47